Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
615 articles about Janssen Pharmaceutical Inc.
-
Rybrevant has been approved for use with carboplatin and pemetrexed in the first-line treatment of locally advanced or metastatic non-small cell lung cancer with exon 20 insertion mutations in the EGFR gene.
-
A federal judge in New Jersey has agreed to hear legal challenges from BMS, J&J, Novartis and Novo Nordisk to the Inflation Reduction Act’s Drug Price Negotiation Program during the same March 7 hearing.
-
Arkuda Therapeutics Announces Option and Asset Purchase Agreement
2/7/2024
Arkuda Therapeutics today announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, which grants Janssen an exclusive option to purchase Arkuda's portfolio of lysosomal function enhancers.
-
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
-
New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)
11/14/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® over standard of care.
-
Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study
11/7/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis who have tested positive for anti-citrullinated protein antibodies a and/or rheumatoid factor, and who have had an inadequate response or intolerance to at least one anti-tumor necrosis factor therapy.
-
The British biopharma and Arrowhead Pharmaceuticals have reached an agreement with J&J’s Janssen to transfer worldwide rights to develop and commercialize JNJ-3989 to GSK.
-
New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement
10/23/2023
Janssen Pharmaceuticals, Inc. today announced new data from the QUASAR Phase 3 Induction Study demonstrating the efficacy and safety profile of TREMFYA® (guselkumab), a selective IL-23 p19 inhibitor, in patients with moderately to severely active ulcerative colitis (UC) through 24 weeks.
-
Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone
10/22/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.
-
TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer
10/22/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin -unresponsive, high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy, showed that 77 percent of patients, 58-90]) achieved a complete response.
-
First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations
10/22/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from an open-label, multicenter Phase 1 study evaluating the safety and efficacy of TAR-210, an intravesical delivery system designed to provide sustained, local release of erdafitinib into the bladder in patients with non-muscle-invasive bladder cancer with select fibroblast growth factor receptor alterations.
-
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select FGFR Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy
10/21/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator choice of intravesical chemotherapy in patients with high-risk non-muscle-invasive bladder cancer and select fibroblast growth factor receptor alterations which recurred after Bacillus Calmette-Guérin therapy.
-
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
10/3/2023
Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E.coli developed by Janssen, currently in Phase 3.
-
Non-small cell lung cancer patients treated with the drug combination saw a statistically significant and clinically meaningful improvement in progression-free survival compared to AstraZeneca’s osimertinib.
-
Janssen Launches National Campaign to Recognize and Increase Support for Advanced Practice Providers Who Care for People Living with Multiple Myeloma
9/26/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with the Advanced Practitioner Society for Hematology and Oncology, announced the launch of Make It HAPPen™, a multi-year effort designed to recognize and support Advanced Practice Providers in the life-changing care they provide to people living with multiple myeloma.
-
As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.
-
At the recommendation of an independent data monitoring committee, J&J decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.
-
Phase 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT®
9/6/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating RYBREVANT.
-
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
9/5/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson will showcase data from its neuropsychiatry portfolio at Psych Congress 2023.
-
Janssen Submits sNDA to the U.S. FDA Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations
8/28/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a sNDA to the FDA seeking full approval of BALVERSA®.